top of page

MigVax’s corona

subunit vaccine

MigVax's Vaccine

MigVax-101 utilizes a chimeric protein to generate three kinds of simultaneous immunological responses: mucosal, blood-based, and cell-mediated immunity. This triple-armed approach provides comprehensive protection against infection by activating all arms of the immune system, allowing for the effective eradication of the invading virus. Its epitopes were designed using computational chemistry of immunogenic epitopes in IBV, MERS, SARS-COV and SAS-COV-2, focusing on neutralizing antibodies and promoting an immune response.

The Main Achievements of the Program

​​Advantages of MigVax’s

COVID-19 Subunit vaccine

  • Platform technology

  • Ease of switching

  • Oral administration

  • Triple-arm immunity

  • Safety

  • Efficient and cost-effective large-scale manufacturing

  • Heterologous Boost

Humoral immunity: Following two injected priming doses, Oral or injected vaccines are comparable for boosting neutralizing antibodies

Mucosal immunity: Oral boosting increased IgA levels in BAL comparable to injected boost

Cellular immunity: Tests In progress

  • Neutralization with S prime and RBD boost is consistent with published literature


  • Preclinical safety


Full preclinical safety study completed

Immediate and Recovery safety tested followed by one or two boosts

No significant safety signals observed in full pre-clinical safety study


MigVax-101 components:

  • 1.Free Receptor Binding Domain (RBD) of the SARS-CoV-2 Spike (S) protein

  • 2.Free Labile toxin B-subunit (LTB)

  • 3.Fused LTB-N3

The presence of free LTB along with the LTB-N fused proteins undergo epithelial endocytosis via GM1 receptors in the oropharyngeal mucosa followed by antigen presentation to the immune cells in the lamina propria

This activates 3 arms of the immune response:

  • 1.Mucosal immunity - IgA anti-RBD/S

  • 2.Humoral immunity - IgG anti-RBD/S

  • 3.Cell-mediated immunity

  • Platform technology: MigVax claims its human vaccine development, based on the development of the avian corona virus IBV vaccine, is a generic system for developing subunit corona virus vaccines. The system includes 3 protein elements (one S and two Ns) fused with an adjuvant carrier protein.

  • Ease of switching: The basis of the current MigVax vaccine is built upon the ability to take avian corona virus proteins and convert them to human corona proteins, making it a viable platform for vaccine development with the ability to adapt against the high rate of COVID-19 virus mutation.[1] This rapid switch to newer mutated proteins is an important advantage compared to other technologies.

  • Oral administration: This has a 2-fold effect. Firstly, the ease of administration, especially essential in mass vaccination; and secondly, the mucosal immunity at the site of administration and site of natural virus port of entry – oral mucosa, tonsils, adenoids.

  • Triple-arm immunity: As mentioned above, the MigVax approach is believed to have three kinds of immunal response: mucosal, through site of administration; humoral, through neutralizing antibodies to S protein; and cellular, induced by N proteins component of the vaccine (mucosal IgA, IgG and T-cell response).

  • Safety: no live viral particles; triple-arm immunity may defend from antibody-dependent enhancement

  • Efficient and cost-effective large-scale manufacturing: This is critical in the case of mass vaccination and may be the limiting factor for other technologies; traditional and confirmed technologies, no risk involved (as opposed to newer technologies).​

Advantages of the MigVax Vaccine
bottom of page